Trending: Britsol Myers Squibb 3Q Results Better Than Expected

16:59 -- Bristol Myers Squibb Co. is one of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The company reported third-quarter financial results after the bell Tuesday which came in better than expected. The company reported third-quarter earnings per share of 75 cents on revenue of $11.2 billion. The company also said it was expecting 2022 EPS in a range between $2.54 and $2.84 per share and was backing its 2022 total sales guidance of $46 billion. Analysts were expecting EPS of 69 cents and sales of $11.1 billion, according to FactSet. The company also said sales of its Revlimib cancer drug declined as generic versions have become available. Dow Jones & Co. owns Factiva. (stephen.nakrosis@wsj.com)

(END) Dow Jones Newswires

October 26, 2022 17:14 ET (21:14 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024